All research
Semaglutide 2026-05-22 EuropePMC

Commentary highlights methodological gaps in interpreting semaglutide's stage-dependent effects on feeding and energy expenditure

Comment on Shah and Ayala. Interpreting Stage-Dependent Changes in Semaglutide Response: From Patterns to Mechanisms

Background

The Shah and Ayala study explored semaglutide's temporal effects on feeding behavior, energy expenditure (EE), and substrate oxidation in obese mice, identifying rapid, gradual, and maintenance phases of weight loss. Understanding the evolving physiology of GLP-1 receptor agonist therapy is crucial due to heterogeneous and dynamic clinical responses. This commentary addresses the methodological rigor in interpreting these complex physiological adaptations, emphasizing the need for robust evidence beyond indirect proxies to fully elucidate semaglutide's mechanisms.

Study Design

Ragozzino et al. critically reviewed the mechanistic interpretations presented in the Shah and Ayala study concerning semaglutide's effects. They focused on how the original study inferred satiation and satiety from behavioral proxies like meal size and number, arguing these constructs require direct assessment via preload paradigms or hormonal profiling. They also scrutinized the interpretation of substrate oxidation shifts from gas-exchange calculations lacking isotopic validation and protein turnover accounting, and challenged the ANCOVA normalization method used for EE maintenance.

Results

The commentary identified several key methodological limitations in the Shah and Ayala study's mechanistic interpretations. They noted that conclusions regarding enhanced satiation and loss of satiety were inferred from indirect behavioral proxies (meal size, meal number) rather than direct assessments like hormonal profiling or neural activity mapping. > Shifts in substrate oxidation were interpreted as coordinated metabolic adaptations, yet these derived solely from gas-exchange calculations that did not account for protein turnover and lacked isotopic validation. Furthermore, the conclusion that semaglutide "maintains" EE was found to rely heavily on ANCOVA normalization using body weight, a covariate altered by the treatment itself, which is known to yield model-dependent outcomes. The authors emphasized that these compelling explanations "remain hypotheses" without more explicit, direct mechanistic validation.


Source: europepmc:epmc_PMC13191377 · Ingested 2026-05-22 · Digest: gemini-2.5-flash